Latest "Placebo Hepatitis Virus Infection" News Stories

14:46 EST 6th December 2016 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 8,600+

Extremely Relevant

Warning: Reactivation of Hepatitis B Virus Coinfection During Treatment of Chronic Hepatitis C Virus Infection

SYNOPSIS: Prior to initiation of hepatitis C virus treatment with direct-acting antivirals, patients should be screened for hepatitis B virus coinfection. Those who are hepatitis B virus-infected should receive ongoing monitoring for flares and reactivation of hepatitis B.

HCV Drug Warning

The FDA will require boxed warnings on labels for certain direct-acting antiviral medications used to treat hepatitis C virus (HCV) infection following reports that the drugs reactivated hepatitis B virus (HBV) infection.

Immune responses and immunopathology in acute and chronic viral hepatitis

Comparing the immune responses to and immunopathogenesis of infection with hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) provides insight into the distinct outcomes of each type of viral hepatitis.

FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C

[10-04-2016] The U.S. Food and Drug Administration (FDA) is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus.

[Comment] Eliminating hepatitis B virus as a global health threat

In The Lancet Infectious Diseases, Shevanthi Nayagam and colleagues1 report a modelling study on the effectiveness of different interventions on the incidence and mortality rate of chronic hepatitis B virus (HBV) infection. To appreciate the implications of this report, we need to understand the context. Chronic viral hepatitis is the seventh leading cause of death worldwide.2 Chronic HBV infectio...

FDA approves Gilead’s Vemlidy to treat chronic hepatitis B virus infection

The US Food and Drug Administration (FDA) has approved Gilead Sciences' Vemlidy (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

Audience: Infectious Disease, Gastroenterology, Patient [Posted 10/04/2016] ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and...

BRIEF-Assembly Biosciences starts Phase 1 program of treatment for Hepatitis B virus infection

* Initiates phase 1 clinical program of abi-h0731 for treatment of chronic hepatitis b virus infection

Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection

Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients.

Researchers identify how hepatitis a virus causes liver injury

Investigators have discovered how hepatitis A virus causes liver injury as well as how the virus could jump from primates to mice. Hepatitis A virus is a vaccine preventable form of infectious hepatitis. HAV is found worldwide and is transmitted through ingestion of food and water that is contaminated with the feces of an infected person.

Janssen begins Phase IIb study of drug combination to treat hepatitis C virus infection

Janssen Research & Development has begun its Phase IIb study of combination of simeprevir, odalasvir and AL-335 to treat chronic hepatitis C virus infection without cirrhosis.

Viral hepatitis: A mouse model of hepatitis A virus infection

Gilead Sciences’ Epclusa gets FDA approval to treat chronic Hepatitis C virus infection

The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Epclusa to treat adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

Alnylam announces phase 1/2 clinical trial of ALN-HBV RNA therapeutic

Alnylam Pharmaceuticals Inc. announced the initiation of its phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNA-interference therapeutic for the treatment of chronic hepatitis B virus infection. The trial will first be conducted on healthy volunteers, then in patients with chronic hepatitis B virus. It is based on encouraging pre-clinical data presented at the...

Research findings provide new avenues to target virus infection

Viral infection is one of the leading medical challenges of the 21st Century, ranging from the Hepatitis C Virus (HCV) epidemic affecting 3% of the global population, to recent outbreaks of West Nile, Zika, and Ebola viruses.

FDA approves Epclusa for treatment of chronic Hepatitis C virus infection –

The post FDA approves Epclusa for treatment of chronic Hepatitis C virus infection – appeared first on LifeSciences Healthcare.

NIH Grants $3 Million to Develop New Hepatitis B Treatments

Hepatitis B virus (HBV) is a viral infection that increases the likelihood of developing liver cancer or liver failure. According to the World Health Organization, an estimated 2 billion people currently are infected with HBV, which is more than 10 times the number of people who have human immunodeficiency virus (HIV). Currently, treatment for

The 2016 Lasker Awards: Hepatitis C Virus—From Discovery to Cure

In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection.

[Comment] Cutting out the roots of acute hepatitis C

Hepatitis C infection is mainly a chronic liver disease with severe complications such as decompensated cirrhosis and liver cancer. Several studies have shown that the consequences of chronic hepatitis C virus (HCV) infection are not confined to the liver but also increase the risk of cardiovascular and renal diseases and cancer.1 Most patients with chronic hepatitis C were infected before 1990, w...

Hep D Virus Infection Tied to Higher Mortality in Patients With HIV/HBV Coinfection

Infection with hepatitis delta virus (HDV) in people with HIV/HBV coinfection is independently associated with higher mortality and more liver-related events, according to new findings. Reuters Health Information

Tricks of Ticking time bomb Hepatitis B Virus

Hepatitis B virus (HBV) causes hepatitis B, an infectious disease that afflicts 230 million people worldwide, thereof 440 000 in Germany. Persistence of the virus in liver cells leads to progressive organ damage in the patient and contributes to a high risk of cirrhosis and liver cancer development....

Novel Test Allows for One-Step Diagnosis of HCV Infection

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient,...

UNC Researchers Identify How Hepatitis A Virus Causes Liver Injury

Hepatitis researchers have long thought that immune cells sent by the body to attack virus-infected cells in the liver cause the acute liver injury associated with hepatitis A virus (HAV) and other hepatitis viruses. Yet, investigators at the University of North Carolina at Chapel Hill have discovered that it is an immediate, intrinsic response of

FDA Approves Epclusa (sofosbuvir and velpatasvir) for Treatment of all Major Forms of Chronic Hepatitis C Virus Infection

June 28, 2016 -- The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis...

[Personal View] Access to treatment for hepatitis C virus infection: time to put patients first

Sound health policy puts patients first. Antiviral regimens approved in 2014 revolutionised treatment of hepatitis C virus (HCV) infection. Most patients can now be cured. These new regimens, however, were priced at US$83 320–150 000 for a 3-month course. Public and private payers in the USA responded by limiting coverage to patients with advanced fibrosis or cirrhosis, keeping the drugs fro...

Quick Search

News Quicklinks